Absci Reports Positive Interim Phase 1 Data for ABS-201
Absci reported positive interim Phase 1 data for its ABS-201 antibody, highlighting a favorable safety profile and long half-life. This early-stage data lays the groundwork for advancing its hair loss and endometriosis treatments.
View filing at SEC.gov →